Partner Headlines - CVM

  1. CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy ...

    Benzinga
  2. Morning Market Losers

    Benzinga
  3. Morning Gainers for Friday, March 14, 2014

    Benzinga
  4. Mid-Day Gainers Mar. 7, 2014: SKUL, SMSI, DLIA, BIG, CVM, KFY, ...

    Benzinga
  5. Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, ...

    Benzinga
  6. CEL-SCI Says Navy Okays Commencement of Co.'s Phase I Trial for ...

    Benzinga
  7. CEL-SCI Prices $3.0M Unit at $0.63/Unit

    Benzinga
  8. CEL-SCI Corporation Announces Proposed Public Offering of Common ...

    Benzinga
  9. CEL-SCI Warrants to Trade Under Ticker Symbol 'CSCIW'

    Benzinga
  10. CEL-SCI Receives Bosnia and Herzegovina Approval to Commence ...

    Benzinga
  11. CEL-SCI Receives Croatian Government Approval to Commence Phase ...

    Benzinga
  12. CEL-SCI, Ergomed Announce Co-Development, Profit Sharing Deal ...

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. CEL-SCI Corporation Announces Proposed Public Offering of Common ...

    Benzinga
  15. CEL-SCI Reports CRADA with Naval Medical Center in San Diego

    Benzinga
  16. CEL-SCI Says NYSE MKT Approves Plan to Return Co. to Listing-Standards ...

    Benzinga
  17. CEL-SCI Corporation to Raise $10.5M in Registered Direct Offering

    Benzinga
  18. Cognizant Technology, Sohu.com Among Stocks Gapping Up Monday

    FoxBusiness
  19. Smith \x26 Wesson Holding Corporation, ValueClick Among Stocks ...

    FoxBusiness
  20. CEL-SCI Corporation Gapping Down Tuesday

    FoxBusiness
  21. CEL-SCI Will Sell 16M Shares at $0.35

    Benzinga
  22. Cel-Sci Says Phase III Clinical Trial Moving Forward

    Benzinga
  23. CEL-SCI Corporation to Raise $5.76M in Registered Direct Offering

    Benzinga
  24. CEL- SCI Corporation Authorizes Expansion of Phase III Clinical ...

    Benzinga
  25. CEL- SCI Corporation Updates Positive Phase III Clinical Activities ...

    Benzinga
Trading Center